Greetings. Welcome to Alcon's first quarter 2026 earnings call. At this time, all participants are in listening mode. A question and answer session will follow the formal presentation. If anyone today should require operator assistance during the conference, please press star zero from your telephone keypad. Please note that this conference is being recorded. At this time, I'll turn the conference over to Dan Cravens, Vice President and Global Head Investor Relations. Thank you. You may now begin.

Welcome to Alcon's First Corner 2026 Earnings Conference Call. Yesterday, we issued our press release, interim financial report, and earnings presentation. All of these documents are available on our website at investor.alcon.com. Joining me on today's call are David Endicott, our Chief Executive Officer, and Tim Stonecipher, our Chief Financial Officer. Before we begin, please note that our press release, presentation, and remarks today will include forward-looking statements, including statements regarding our future outlook. We undertake no obligation to update these statements as a result of new information or future events, except as required by law. Actual results may differ materially from those expressed or implied in these forward-looking statements. Please do not place undue reliance on them. Important factors that could cause actual results to differ are included in our Form 20F, Earnings Press Reliefs, and Interim Financial Report, each of which is on file with the Securities Exchange Commission and available on their website at sec.gov. We will discuss certain non-IFRS financial measures. These measures may be calculated differently from and may not be comparable to similar measures used by other companies. They should be considered in addition to and not as a substitute for IFRS-prescribed performance measures. Reconciliation between our non-IFRS measures and the most directly comparable IFRS measures can be found in our earnings press release. For discussion purposes, our comments on growth rates are expressed in constant currency. In a moment, David will begin with highlights from the first quarter. After his remarks, Tim will walk through our financial performance and outlook for the remainder of 2026. David will then return with closing comments before we open the line for Q&A. Before I turn the call over, I'd like to share that Alan Trang has accepted a new finance leadership role within Alcan, supporting our surgical business in Singapore. On a personal note, I want to thank Alan for his deep expertise, sound judgment, and the partnership and friendship he has brought to our team and to our engagement with the investment community. He has made a meaningful impact on Alcon. And while we'll miss him in his current role, we're excited to see him take on this next chapter within the company. And we expect to announce Alan's replacement in the near future. With that, I'll turn the call over to our CEO, David Endicott.

Good afternoon, and thanks for joining us. Let me start by recognizing the incredible work of our talented teams around the world. Your ongoing dedication, innovation, and commitment to our customers continue to move Alcon forward and make a meaningful difference in patients' lives. Now, the first quarter was an important step forward for our new products, demonstrating strong market acceptance and share gains. In a quarter marked by uneven market conditions, particularly in Cataract, our team stayed focused and delivered results that reflect the strength of our innovative portfolio. Our recent product launches contributed meaningfully to top-line growth in the first quarter, and we expect that contribution to continue to build as the year progresses. Importantly, we're seeing market share gains across key categories, particularly in U.S. ATI wells, surgical equipment, and consumables, and contact lenses, as well as dry eye. That momentum was clear at the ASCRS meeting last month. Across more than 60 presentations and peer-to-peer sessions, we saw strong surgeon engagement driven by impactful scientific data and hands-on demonstrations. Discussions focused on consistency, workflow integration, and matching technology to patient and doctor needs. This real-time feedback reinforces our confidence in our ability to translate innovation into real-world clinical value. I'll now move to discussing recent innovations, starting with our Unity Fake Ovit device. As we've discussed in the past, the Unity platform represents our most significant equipment upgrade opportunity in more than a decade, and the scientific community continues to recognize that. In addition to previous top innovation awards, I'm pleased to report that UnityVCS was named an Edison Award winner last week. This is one of the most recognized honors for market-ready innovation and reflects its meaningful impact on surgical technology. Launched in 2025, Unity VCS is engineered to enhance surgeon control, improve efficiency, and streamline the surgical workflow. VCS has been introduced across most major markets worldwide and continues to build momentum and perform well in the quarter. And late last year, we expanded the platform with Unity CS, our standalone cataract system. It's designed to increase surgical throughput while maintaining precision and safety. Unity CS has also been very well received. Surgeons have noted its seamless workflow and next-generation energy delivery that help optimize case efficiency without compromising outcomes. With a substantial installed base of legacy machines and a compelling value proposition across both efficiency and clinical performance, Unity represents a significant technology upgrade. Beyond the replacement market, Unity is also showing strengthening share and actually expanding our installed base. As a result, our order pipeline remains robust, especially post-ASCRS. We'll continue to work closely with customers to manage OR installations with the quality, service, and support they expect from Alcon. Now, I'll turn to Implantables, where our innovation is strengthening our competitive position and driving solid performance. In fact, in the U.S., we gain share in every IOL category in the first quarter. I'll start with Panoptix Pro, our latest trifocal IOL. Pro builds on the proven success of Panoptics, which is already the world's number one most implanted trifocal with over 4 million implants. Pro introduces new features that reduce light scatter and delivers greater quality of vision. In the U.S., this lens has helped to drive almost two share points of growth in the PCIOL category. Internationally, we're just getting started. We recently had an upcoming launch in Australia, Japan, South Korea, and now Europe. Feedback from these launches has been positive, and we're confident that Panoptics Pro will bolster our presbyopia-correcting eye-well leadership globally. Building on Panoptic Pro's momentum, we launched TruPlus, our new enhanced monofocal eye-well. This lens extends the range of vision of a traditional monofocal, providing enhanced intermediate vision without compromising distance performance. TruPlus is designed for surgeons who want an enhanced monofocal option. It enables us to compete more effectively while defending our Clarion monofocal base. Importantly, TruePlus launches with a TORIC version from day one, and having a TORIC modality is a meaningful advantage for competing in the astigmatism correcting segment and growing our ATIOL share. Finally, we remain on track to launch an upgraded version of Vividi, our extended depth focus IOL, in early 2027. With more than 2 million implants, Vivid is already the world's most implanted Edof lens, and this enhancement is designed to improve near vision while preserving Vivid's low visual disturbance profile. Now I'll move to retina, where Valeda, our photobiomodulation device for intermediate dry AMD, continues to see encouraging early adoption. Valeda is the first and only therapy clinically shown to maintain vision improvement in dry AMD patients. with some patients achieving about a one-line gain in visual acuity. This technology uses three specific wavelengths of light to improve mitochondrial activity and retinal health, giving retina specialists a non-invasive treatment option for dry AMD that they've never had before. Importantly, reimbursement is progressing, with all but one Medicare administrative contractor covering Valeta, and we're actively engaging private payers and expanding physician education. The latest complements Voyager by expanding our office-based procedures, enabling practices to operate more efficiently while offering patients convenient, non-invasive options. Now I'll move to contact lenses, where we continue to gain traction with our innovative reusable portfolio. More than half of new wearers start in reusables, which is a segment that supports strong patient retention and delivers highly attractive margins. Given our under-indexed share position, this category remains an important growth opportunity for us. Our reusable portfolio is anchored by Total30, the industry's first and only monthly lens, with water gradient technology, which delivers exceptional comfort for 30 days of wear. Last year, we expanded the Total30 family to cover all major modalities, sphere, toric, and multifocal. And in February, we introduced Total30 Multifocal for astigmatism, which is our first multifocal toric contact lens. This lens fills an important, unmet need for presbyopic patients with astigmatism, a group that historically has had very few options. Initial feedback has been excellent, with ECPs highlighting crisp vision at all distances and long-lasting comfort. Alongside Total 30, Precision 7 broadens our portfolio with a high-quality, accessible, one-week replacement lens. Designed for patients where daily disposables are not an option, Precision 7 delivers a comfortable experience at an attractive price point while introducing a replacement schedule that many optometrists view as more intuitive than traditional two-week lenses. Combined, these innovations drove share gains in the quarter, and we are expected to continue to do so in this category. Finally, in ocular health, we continue to strengthen our leadership in the expanding dry eye category through innovation in both our over-the-counter and pharmaceutical products. On the over-the-counter side, our Sustained family of artificial tiers delivered another quarter of high single-digit growth. Most notably, last year we launched Sustained Pro, our most advanced artificial tier. Its triple-action formula is designed to hydrate, restore, and protect the oculus surface, delivering long-lasting relief. Early performance has been strong, contributing to continued share gains in U.S. artificial tiers and reinforcing our leadership as that category expands. In pharmaceuticals, TripTier continues to perform well. Doctors appreciate its rapid onset and novel mechanism of action. Importantly, TripTier is already capturing share with approximately four share points in just eight months into the launch. We've also made great progress with payers. In the first quarter, we expanded coverage to more than half of our commercial lives. Our focus for the remainder of the year is on broadening the prescriber base and securing future Medicare Part D coverage, which will significantly expand patient access and make Triptir easier to prescribe. Triptir and SustainPro together represent significant innovation in dry eye, extending our reach across the full spectrum of dry eye sufferers and reinforcing Alcon's leadership in this category. Looking ahead, our innovation pipeline remains strong. with upcoming launches, including a new entry into an eye-whitening category, as well as Unity M, our newest microscope, and Unity DX, our whole eye diagnostic device. And these programs build on the momentum we're seeing across the portfolio and reflect our continued focus on advancing differentiated innovation. Together, they reinforce our confidence in the durability of our pipeline and our ability to drive sustained growth over time. now i'd like to turn to operational improvements where we are making a number of things happen internally as we scale innovation across the portfolio artificial intelligence has become an important enabler at alcon helping us operate faster and make better decisions we started applying ai selectively where it enhances productivity quality and speed in r&d we've deployed solutions that we expect will increase speed to approval while working on ai-enabled modeling and simulation for accelerating design and development. In operations and quality, we are leveraging AI solutions to improve yield and perform automated inspections. And on the commercial side, AI-assisted analytics are enabling deeper customer insights and more personalized engagement. So while it's still early in our journey with AI, these advancements are fortifying our operational foundation at a pivotal moment and enabling us to leverage a more stable cost structure, and seize emerging opportunities. Now, before I close, I want to share a few observations on the market environment. In cataract surgery, consistent with prior quarters, we estimate that global procedure volumes grew low single digits. While this relative softness has persisted for several quarters, we continue to believe that market growth will return to historical levels as healthcare systems adapt to increasing demand. However, for 2026, our guidance continues to assume that current trends continue. On the other hand, we estimate that global ATI well penetration was up 130 basis points to approximately 17%. There was broad-based strength in most regions of the globe, which was pressured by weakness in China. If you were to exclude China, global penetration was up approximately 220 basis points. In contact lenses, we estimate the global market grew at the low end of mid-single digits, led by strength in the United States. In summary, while market conditions remain mixed, our strong portfolio of innovation is performing well and continues to deliver solid results. We're operating from a position of greater strength backed by a deeper innovation engine and a more resilient commercial model. This positions us to deliver durable, profitable growth and create meaningful long-term value for shareholders. With that, I'll turn the call over to Tim who will walk you through the financials.

Thanks, David. Our first quarter sales of $2.7 billion were up 6% versus prior year. In our surgical franchise, revenue was up 6% year-over-year to $1.5 billion. And plannable sales were $438 million in the quarter, up 1% versus the prior year period. As David mentioned, Panoptics Pro continued to perform well. We saw solid growth in IOLs in the U.S., partially offset by ongoing competitive pressures internationally. We also saw some pressure in surgical glaucoma. In consumables, first quarter sales of $769 million were up 4%, which reflects softer than historical market conditions as well as price increases. In equipment, we saw another quarter of accelerating growth with sales of $253 million, up 23%, driven by strong momentum from Unity. Early adoption has been encouraging, and we're seeing Unity act as a meaningful catalyst for equipment growth. Turning to vision care, first quarter sales of $1.2 billion were up 6%. Contact line sales were up 4% to $738 million. This growth is primarily driven by product innovation and price increases, partially offset by declines in legacy products where we've limited our promotional activity. In ocular health, first quarter sales of $487 million were up 10%, led by continued strength of our dry eye portfolio, including trip care and sustain. Triptier continues to perform well, with strong refill rates and broad prescriber enthusiasm. As access expands and awareness builds, we continue to expect Triptier to be a meaningful growth driver this year. And as David mentioned, our sustained family of eye drops also had another great quarter, with high single-digit growth. Within that portfolio, our multi-dose preservative-free formulations contributed nicely, growing more than 20% year over year. Now, moving down the income statement. First quarter core gross margin was 53%, down 40 basis points year-over-year. This is primarily due to 120 basis points of pressure from incremental tariffs. Core operating margin was 21.2%, which was flat year-over-year. Improved operating leverage from higher sales and manufacturing efficiencies were partially offset by the pressure from tariffs that I just mentioned, as well as investment behind new product launches and R&D. The first quarter interest expense was $52 million, and other financial income and expense was a net benefit of $2 million. The average core tax rate in the first quarter was 19.7%, down from 21% in the prior year. And finally, core diluted earnings were $0.85 per share in the quarter. Turning to cash, we generated $279 million of free cash flow in the first quarter, which was flat when compared to the same period last year. Lastly, with respect to tariffs, we incurred $33 million of incremental tariff-related charges in the first quarter, which was recognized in cost of sales. Now, moving to our outlook for the remainder of the year. Our outlook assumes that aggregate eye care markets grow 3% to 4% for the year, that exchange rates as of the end of April hold through year end, and regarding tariffs, we are now assuming that an average tariff rate of approximately 10% on U.S. imports' holds for the remainder of the year versus our previous assumption of 15%. We also assume retaliatory tariffs remain unchanged. This change results in an estimated $25 million reduction in tariff expense versus our February guidance, which we would expect to reinvest back into the business. Based on these assumptions and our performance through the first quarter, our guidance is as We continue to expect constant currency sales growth of between 5% and 7%. Turning to margin, we continue to expect core operating margin expansion of between 70 and 170 basis points. We expect the majority of this expansion to occur in the second half of the year. As in prior years, SG&A is expected to peak in the second quarter due to normal seasonality with incremental spend this year in support of product launches. Accordingly, we expect second quarter core operating margin to be below the prior year period. And lastly, we now expect core diluted EPS growth of between 10% and 13%. Moving on, I'm happy to announce that our board has approved a new $1.5 billion share repurchase program to be executed over the next three years. This authorization reflects the strength of our balance sheet and robust cash flow generation and is fully aligned with our longstanding capital allocation priorities. We will continue to prioritize investment and top-line growth through R&D and discipline, bolt-on M&A. This program enables us to return incremental capital to shareholders in a measured and disciplined way without constraining our ability to fund growth or maintain a healthy deal pipeline. And before I wrap up, I'm also pleased to report that at our annual general meeting last week, our shareholders approved a dividend of 28 Swiss centimes per share, which we expect to pay on or around May 7th. I'd like to thank our shareholders for their continued support. And lastly, I'd also like to extend my thanks to our more than 25,000 associates across the organization for their dedication and hard work. And with that, I'll turn it back to David.

Thanks, Jim. To close, the first quarter underscored the strength of our business. Our steady cadence of innovation, balanced portfolio, and strong execution are driving durable performance across the company. New product launches are gaining traction, our pipeline continues to advance, and we're utilizing tools like AI to help us operate with greater speed, precision, and scale. Taken together, these advantages position Alcon to navigate the environment with confidence and deliver steady, profitable growth and long-term value for our shareholders. With that, operator, please open the line for questions.

Thank you, everyone. We'll now be conducting a question and answer session. If you'd like to ask a question at this time, please press star 1 from your telephone keypad and a confirmation tone to indicate your line is in the question queue. You may press star 2 if you'd like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. To allow as many as possible to ask questions, we ask you please limit yourself to one question and one follow-up. Thank you. And our first question today is from the line of Ryan Zimmerman with BTIG. Please proceed with your questions.

Good morning, David and Tim. Thanks for taking the question. Maybe to start with the implantable category growth for a minute here, David. You know, if you look at the growth over the last five quarters or so, you know, you think about the peers and the category, it's been a bit below that market rate. And so, you know, I'm wondering how much you, you know, is surgical glaucoma dragging down your growth, you know, given what you're seeing in Panoptix Pro and, you know, the Clarion launch. And, you know, if you could kind of parse out what's China, VVP versus glaucoma versus, you know, maybe more of your core ATIOL adoption. I'd appreciate it.

Yeah, thanks. Thanks, Ryan. Really, really good question. Look, the 1% growth on the implantables broadly, you know, is made up of a number of things. And, you know, one of the reasons we kind of called out, you know, glaucoma implantables is because, as you know, the reimbursement changed this year. And we also had about a $3, $4 million kind of supply issue on Hydrus kind of late in the quarter. So, you know, our core growth there actually, when you back just the Hydrus piece out, you know, is about 3%. If you looked at it in the U.S., it was 6%, so we had a very good quarter in the U.S., and if you look at it without China, it gets higher because China, we had, as we kind of moved forward with BBP last year, you know, we had some inventory come in, so the comp is a little bit big. So we've actually had a pretty good quarter in implantables around the world, various markets. You know, I think as we go forward, Panoptix Pro really looks to be doing very well. I think in the U.S. in particular, we gained share in the implantables. You know, it was a, I think we gained in 80 IOLs, you know, more than a share point of 1.4, I think. We were up total IOLs 2.2. So, you know, we've stabilized that market a bit. And I think we're feeling like once we get pro into, you know, Europe, which is just launching this month, it's had a nice reception in Japan, but we just got that in, I think, in February. So, you know, we're getting, you know, we're getting a number of other markets now as we launch those doing well. And I think when you add to that true plus and then, you know, you think about going forward at the end of the year, we've got a Vividi Pro. We won't have the same kind of exposure for long duration of periods to competitive products. Most of the products you're seeing right now come into the market we've seen for a long time. So, you know, we've got a number of new things, you know, right now coming in that are hopefully going to offset it. Make no mistake, it's going to be competitive. And, you know, I think what we've said in the past and I still would reiterate is, you know, I think we can grow at market rate here. But it's going to be competitive. The best thing that happened, honestly, was ATI Wells, you know, was up 230 basis points in the U.S. So, you know, really nice movement around the world on ATI Well penetration. And, you know, we seem to be doing pretty well right now in the U.S. You know, we'll see how that takes shape as other products launch. But I generally think it's going to be a competitive fight. But, you know, pretty healthy position we're in.

And maybe for Tim, you know, gross margins came in a bit better than I think the street was looking for here. You know, it sounds like some of that was price. You have a little bit less of a tariff impact. You're not assuming refunds. I'm just wondering kind of, you know, with gross margins trending higher than maybe the street was looking for, you know, one, what are your expectations there? But, two, why can't that flow through at a higher level to the op margin line and, you know, subsequently EPS?

Yeah, I think you got the pieces of the pie correct. I mean, we did still see tariff pressure. So when you look at it from a year-over-year perspective, the rate cuts that we talked about, those really will hit in the back half of the year, you know, starting, I think it's in March. But, listen, we're seeing some nice, when you take into account the projects we're working on and our manufacturing plants from a productivity perspective, to your point, we are still getting price. So I'd expect those margins, the gross margin, to continue to be in that neighborhood of 63% as we go out through the course of the year. Thank you.

Our next questions are from the line of Veronica at Java with Citi. Please proceed with your questions.

Hi, guys, and thank you for taking my questions. Just first one, kind of how you think about the market momentum, I guess. Lots of moving parts, obviously, in Q1, especially on the surgical side with weather and some strikes that some of your peers have called out. But I'm just curious. I think, you know, you described the market growing as 3% in Q4. Sounds like maybe Q1 on the surgical side was a little bit softer. What's your degree of confidence that we're going to be within that 3% to 4% range that you guided for for the year? And I guess to what extent, you know, you're seeing a momentum that has improved looking at March and April. If you can comment on that, that'd be super helpful. And then my second question is on contact lenses. We've seen the gap between you and the market really narrow, and looking at the last couple of quarters, certainly on a sort of sell-in perspective, it seems to be that you are tracking market very, very closely. I was just hoping, David, you can talk about how you feel about the competitive dynamics there and your degree of confidence and your ability to outgrow that market as we look through the remainder of the year. Thank you guys so much.

Yeah, thanks, Veronica. Let me start with the surgical market. You know, yeah, there were strikes, there was weather, there was all that stuff going on, and I do think some of that had some effect. But I think the way to think about this market is kind of as we described it, 3% to 4%, remember, is the aggregate market number for us. So that is contact lenses, which grows 4% to 6% generally, the cataract market, which, again, generally grows kind of in that 3% range. And then you've got the pharmaceutical markets and the OTC markets, and those grow, you know, right now a little bit better than that. So we are confident in that three to four range. In the quarter, we were on the lower end of that because, frankly, the U.S. market in surgical was soft. And so, you know, we can put it in the weather, we can put it on stretch, we can do any of that stuff. But I think at the core of it, there is a lot of demand for cataracts that is not currently being met. The demand for cataract is very high. A number of days of wait time has gone up. And I think what's really happening, and we've been seeing it for a while, is this kind of restructuring of the service, the workflow here. Surgeons are hiring optometrists. They're using office-based surgery. They're finding more ASC time in other places. But to do that, it takes a little bit of time. And I think as they work through, you know, to try and capture the economics of what is kind of a, I don't want to say an unlimited demand, but there's plenty of cataracts out there to do. They need to find more OR time, and they need to do more in a day, and that's what they're working through right now. So as we see three to four going forward, I don't really think there's a big change in the U.S. cataract market this year. We kind of called the market as we saw it at the beginning of the year. We think that continues all year. But I do think we feel comfortable with that range in aggregate. So, again, there'll be some markets that bounce around a little bit more than others, but that's where we are right now. On the other point on the contact lenses, what I'd say is that, you know, we've done real well with a lot of our products. I think reusable, one of the things you'll note is that, you know, for example, we gained, I think, a SharePoint change on reusables. But our dailies business was a little bit flat. It was slightly up. I think we were only one of two, I think, of the bunch of us that gained share. So we are gaining share, but it is more modest than it was when we first came out with P1 or with T30. We're getting a lot of share in the U.S. right now in reusables. We're getting a lot of share in dailies in the international markets. And then we're kind of losing it. We're kind of flattish in the U.S. on dailies. So I would say it's a mixed bag. But I do think that if you look at where we are with, for example, Precision 7 and Total 30, we're continuing to grow above market. I think the drawdown on dailies has been our legacy business. So if you think about that legacy business, which is kind of getting smaller and smaller, the front half is bigger than the back half, obviously. And so our comp gets a little easier as you move to the back. And that's kind of the – that's really the story of the year, which is a pretty level-loaded year broadly. I think what's important to know is that the acceleration of new products really takes off, you know, kind of front half, let's call it a third or a little bit more than that, and the back half kind of two-thirds, a little bit more than that. That's the truth on all the new products.

Got it. Thanks, guys.

Our next question is coming from the line of Matt Mixick with Barclays. Pleasure to see you with your questions.

Hey, thanks so much. Can you hear me okay? So, listen, I appreciate the color on the market, and congrats on the progress on PanObjects Pro. I was just wondering if you could talk a little bit about the effect of some of the pull-through that you've seen from the Unity renewals in terms of either kind of locking down or taking more share in monofocal Iowa growth. And then I had one quick follow-up.

Well, it's a really good question, Matt, because we did actually see it. I didn't really mention it, but we took a fair bit of share in Monofocal, actually, in the quarter globally. And, you know, some of that has to do with our presence in the OR. And when you're selling more stuff in the OR, then, you know, you can generally sell more stuff. So that's the, you know, the view that we have on that. So it is connected at one level because we've got a lot of people in the OR right now with a lot of new products. So, you know, I think that's been a very positive. I would just say that the ATIOL business is still the one we pay most attention to because, you know, globally, you know, we've got a challenge, I would say, in the international markets, and we're stabilized and kind of beginning to grow again in the U.S. market. But, again, there's more competition coming. So I'd say the fight is really ATIOLs, but you're not wrong. We are gaining a good bit of share in the monofocal business. On the Unity process itself, obviously, the other thing that helps is we just launched CS. And so the benefit of that is, of course, it's a little easier to install. It takes a little less time. It's a less complicated machine and requires a little less hand-holding. So we're looking forward to – and there's a lot of cataract surgeons. So just in terms of total sheer number of placements, we're in a lot more ORs right now as we start to expand beyond retina and really kind of begin to sell the CS machine. So that, again, gives us an opportunity to sell viscoelastics, sell BSS, sell all kinds of stuff that we generally do. So a really good, important point you're making.

Our next question has come from the line of Jack Reynolds-Clark with RBC Capital Markets. Pleased to see what's your question.

Hi there. Thank you for taking the questions. My first was just coming back to the kind of surgical cataract market. um with these waiting lists so so long what is it that can you just kind of just talk us through exactly what needs to happen for this demand to translate into a higher market growth and when when that's going to happen okay is it going to be a 27 28 thing kind of what what are the drivers there um and then on ati well penetration um so could you just remind us what it was uh in europe and how you see that progressing over the next kind of couple of years? Do you expect to catch up with the U.S. or something like that?

Yeah, look, I mean, I think let me answer the second one while I've got the data in front of me. I mean, I think the Europe PC ATI well penetration, you know, was pretty good on the quarter. directionally it was 16.1%, and it was up 260 basis points, so almost the same as the U.S., a little better than that. It was 230 in the U.S. The only thing that kept it down was China went the wrong direction because there was a recall from one of our competitors, so the data looks a little weird there. But fundamentally, most markets are beginning to catch up to the U.S., So, you know, I think the U.S. is sitting somewhere in the 20s, like 21 or something, and so you've got a relative comparison. I do think that historically this market penetration has grown 50 to 100 basis points. I would still draw that line. I think what you're seeing right now is a lot of promotion from a lot of companies, and that's moving people towards ATI Wells, which is a good thing. There's a lot of room in this market to grow, and I think, you know, the upper limit I think we've said in the past is, you know, maybe mid-30s to, you know, upper level. you know, high 30s, but, you know, that's the ceiling. So it's not everybody going to use one of these, but they're worth a lot more to us on a value basis. So moving this market along, I think, is a very positive sign. On the other point you make, which is the surgical market and what it takes to translate demand into revenue, I think that's the big question that most PE guys have in the U.S. It's what all the big practices are working on. And at the core of it, it really is freeing up time to do more surgery. I mean, it's just that simple. But that's not so easy when you're competing with, for example, a hospital OPD who wants to give that time to a more productive, more economically valuable procedure somewhere else. So certain parts of the market are shrinking for available time, and certain parts are growing. So what's really happening right now is you're seeing this rotation into things like office-based surgery, which is very popular right now. It's gaining some momentum in the U.S. where they're putting office facilities in play that can carry our machines, microscopes. They're setting them up to do surgery. It's a friendlier environment. The reimbursement is still, you know, complicated, but I would just say that that's creating more capacity and more flexibility for the surgeon. I think the other thing that happens is you see a lot more ODs entering practices with large group practices, PE groups, even small practices you know that i was in one in recently in boston where they were you know hired just hired two ods and they're doing you know some primary care work and some pre and post-op work and that frees the surgeon to do more time in the or so that's the that's the adaptation of practice pattern that has to occur and it's going to take some time i mean i think that's really why you know we've seen kind of unabated growth by bringing down the time in surgery you know that the time in surgery is going to only get better by a little bit now We're flipping rooms just a little bit almost as fast as we can. We'll get a little bit better there with our machine. But I think the opportunity here is really now to see more days in surgery from the core surgeons.

That's super clear.

The next question is from the line of Susanna Ludwig with Bernstein. Please receive your questions.

Good afternoon, and thanks for taking my questions. I guess my first is just on contact lenses. If you could talk a little bit more on the drivers of growth and the contribution from volume price and the mixed shift to dailies. And then maybe just a little bit about your performance geographically in the U.S. versus Europe versus Japan. And then second, just to follow up on the questions on IOLs, you have noted sort of heightened competitive pressure in IOLs and international markets for several quarters now. Could you talk maybe about how this pressure has progressed sequentially and when you will start to lap some of that pressure?

Yeah, let me take him on first with the first bit of that, which was the contact lens market. Historically, I think the way to think about the contact lens market is we've always said it's kind of mid-single-digit grower, 4% to 6%. Price is 2% to 3%. Mix is 2% to 3%. Volume basically has been flat. You know, you pick up 14-year-olds, you lose 40-year-olds. probably about the same rate. What I think is happening right now, and most recently, has been the resistance to price internationally in particular, where chains and the internet have a bigger participation in the process, and they're very sensitive to consumers. So I would say, you know, what's really gone on is there's a pause in the ability to push price into the market. That's certainly what we see. I think that's really what's driving a little bit of a slower market. But again, we're still in the normal range. I would just say we're on the low end of the normal range there. So going forward, I think what you're going to see is as the consumer gets a little bit stronger and as you see new products and mix, in particular for us, the mix to reusables, the mix to dailies generally allows us to help outperform. We're also gaining share there. So I think both of those will allow us to kind of grow a little faster than that market. On the geographic performance outside the U.S., you know, the IOLs, you know, our share in the U.S. has been stabilized principally on the back of Panoptix Pro. And we really didn't have a new product in the international market until really Japan at the beginning of this year. So I think what you're going to see is a similar playback, you know, where you've got, you know, some other pressures coming in. I think, you know, Odyssey will come in. But again, I think we've seen both of these products, you know, in the past in different markets, and we've got data now on them, which I think will help manage, let me just say, the impact on that. So the share movements, you know, have always been a little bit more significant outside the U.S., where we have, you know, I think a more competitive market where there's more products. And so I think, you know, we continue to believe that the introduction of products, meaning specifically panoptics pro then true plus uh then vividy you know the next vividy 20 i guess that's the that's the way out of this thing and so it looks pretty good to us great thanks our next questions are from the line of graham doyle with ubs please receive your questions oh yeah thanks a lot for taking the question it's just just one and in the context of the phasing uh through this year's you just printed a six against what we think is a which was the easiest comp in the year at least

And therefore, I think you can see in the share price today, there's disappointment that maybe we're looking at sort of slowing growth or no improvement from here. Is that a reasonable way of thinking, or is there actually scope here for growth to improve as you go through the quarters? It'd be good to get that sense, please.

Well, Graham, let me just let's clarify the comp itself and the number itself. You know, we had a number of things happen that would have, I think, maybe changed the optics on this a little bit. But, you know, the Middle East piece of this is that disruption was worth $11 million in shipping to us, which was probably 50 basis points of growth. And then I think if you take the hydrous piece, there's another 10 basis points. So, you know, I think on 6-1, which is where we ended, we would have been something closer to like 6-7, 6-8, something like that. I mean, I think, candidly, we've had a level-loaded plan for a while. and you know what you really see is you know that the front edge of this the front half of this year is going to be a lower amount of new products and the back half is going to be a much higher amount of new products and so you're going to see that acceleration kind of coming around on the next comp you know which is slightly better than last than the front half on a comp basis you know that's that's how you make up for it so i think you know we've had a point of view on this one from the beginning that, you know, we were pretty close, you know, to the right answer, you know, from the beginning of the year, which is markets are going to be kind of three to four, which is a little softer than we've seen in the past, but new product flow is going to make up for it and it accelerates in the back half.

Okay. So fair to say you'd hope to maintain this momentum and, you know, avoid the sort of hydrous and Middle East shipping issues in the next few quarters effectively.

Yeah. I mean, I think that's probably fair, right? I mean, I don't think we believe that we're going to have that challenge. One of them was an outage that we created, so that's a solved problem with Hydrus already. And then I think the other piece is we'll have to see, but I'm not a prognosticator on the Middle East. So what I would say is we just watch and see, but that was obviously a problem for us.

No, that's super helpful. Thanks a lot, guys.

The next questions are from the line of David Saxon with Needham & Company. Please receive your questions.

Thanks, guys, for taking my questions. Congrats on the quarter. Wanted to ask on Triptier, David or Tim, maybe you can talk about the contribution to growth there, what kind of traction you're seeing in existing accounts and kind of how you're positioning it for expanding the prescriber base as you kind of move into the next wave.

Yeah, David, we're very excited about what's going on with Triptier and the response. I mean, I don't know that we knew precisely. You know, you never know for sure until you get a product into the market and you have an opportunity to watch it for a while. I think we're at a place now where we have a pretty good feel for it. Our refill rates are 70 plus, which is really great. I mean, I think there was, you know, there was some criticism, I think, about, you know, the comfort of this product. I think what patients are finding is that it is worth, you know, it does have a little bite to it when we put it in, but at the same time, feel relief quickly. And that relief day one is worth it. And so I think what we're seeing is two things, patient acceptance as a function of refill rates, and then the breadth of prescribing now has gone very wide. So I think we're getting a lot of trial from the full audience. And so I think our Salesforce done a terrific job of getting out to everybody, but also you're seeing kind of repeat prescriptions and refills come nicely along. So that, I mean, you know, the big thing here, like all pharmaceutical products, is going to be reimbursement. We're about 55% of commercial lives right now covered. We expect that to grow throughout the rest of this year. And, you know, obviously as we go into next year, you know, we're expecting to have, you know, Medicare coverage come through so that we'll be kind of positioned for a full run next year. But, you know, definitely on plan for us, maybe a little bit better than expected.

Okay, great. Thanks for that. And then just on implantables, I know a lot of focuses on, you know, Panoptix Pro and Vividi, but would love to hear how you're thinking about the TruePlus launch, kind of frame it in terms of how meaningful that could be to recapture some of the share you lost to kind of the competitive Monofocal Plus launches from the last couple of years. Thanks so much.

Yeah, it's a good question. You know, and I'm going to, you know, I'll just tell you this much. I think the TruPlus brand is a terrific product, and, you know, this product actually has got better intermediate than alternatives out there, and it has, you know, the same kind of monofocal distance that you would expect that you want from a monofocal. So, you know, if you're going to use and charge a patient, particularly a TORIC patient, you know, for a monofocal plus product, this is going to be, I think, a terrific choice for you because it's going to give them a little bit more intermediate than what's available without compromising, you know, any of the kind of monofocal qualities that we would want. I do think, you know, we did lose, you know, in the TORIC business in particular, you know, we lost in the U.S., I don't know, about 10 share points to TORIC competitors. And I think that, you know, internationally, the market size is a little bit bigger than that. I don't know that this is going to be a big product incrementally. I do think it will cannibalize and sustain our core business. And so think about it maybe more as an upgrade to our current TORIC monofocal, our current monofocal with a slight price increase and, you know, a real safety margin for, you know, competitive intrusion. Because I don't think anybody is going to be able to match this particular brand to the Clarion platform.

Great. Thanks for that. The next questions are from the line of Stephen Lichtman with William Blair. Please receive your questions.

Hi, guys. Maybe start, Tim, with one quarter complete here, I'm wondering if you can provide any more color on the operating margin guidance range and whether you see a trending toward upper half or lower half for the year. You know, it seems like FX will be less of a tailwind, but you have the efficiencies kicking in, And I think you said QQ will be down year over year, so it puts more emphasis on second half. So any further color within that range would be helpful. And then I have one quick follow-up.

Yeah, I mean, the 70 to 170 basis point improvement that we guided towards, we're very comfortable with. That's in constant currency, so just keep that in mind. Q2 will be light, as we've talked about. And as you've seen, if you go back and look at our historical financials, it's a heavy investment period for us from an SG&A perspective. when you think about back-to-school programs and other programs like that. So first half op margin will be, you know, lower than the second half. That will start to accelerate in Q3 and Q4. But overall, we feel very good about the 70 to 170 basis point improvement.

Okay. And then just quickly on the accommodating tunable IOL, any further color when we could see that early data? I think you talked maybe either 2-2 call or 3-2 call.

Yeah, I think somewhere between here and the next call. I think, you know, we certainly expect that data to come through. I think we've got most of it in-house now. We're looking at it probably mid-year, as I think I said last call.

Okay, great. The next questions are from the line of Young Lee with Jeffries. Please receive their questions.

Thanks for taking the questions. I guess to start, maybe just one more on the guidance. So, you know, 1Q was the easiest comp of the year. It seems like Unity and Triptier are doing better than expected, but, you know, hitting the midpoint of the full-year guidance implies a pretty sizable ramp against tougher comps.

I guess, can I just maybe push you on, you know, thoughts on which segments gets meaningfully better from here and uh which segments are going to be the laggers well i mean i would i would think about i would go to the new product flow this easiest way to think about it is is i think we have i can't count the number at this point but i think there's 10 maybe six that are big uh new product flow you know new products um almost all of them came out middle of last year um so if you think about the back half of last year and product flow really you know we got a little bit in the fourth quarter. Um, but you know, what really you're seeing now is, is a pickup, um, you know, that's meaningful, you know, for the full year effect. And so by the time you get to the fourth quarter, you're kind of 18 months into some of these products, which is really, you know, we should be, you know, moving quite well. Um, I would say, you know, all of, you know, most of the big ones, let's call it unity trip tier, uh, pro, um, you know, and I think don't forget our OTC brands, you know, those are doing really well right now. You know, I think one of the underestimated parts of our business tends to be the ocular health business. It's the same size as the implantables and similar profitability, and it's growing, I think, at 10%. So, you know, I do think that if you just kind of go through the list of products and think about when they were launched and what they're wrapping around on the back half of last year, you'll find where the growth comes from because the core business is going to continue to grow roughly at the core market, slightly better maybe because we gained some share, but that's basically where we are.

All right, great. Very helpful. And I guess on the implantables growth, you know, there wasn't a major competitive launch in OneQ. Going forward, there will be. You know, for this year, I think you're expecting around 2% growth. How much competitive Trilin is baked into that number? Is 2% still the right number for annual growth?

Yeah, I don't know that we've guided individual categories, but I would just say that we're very excited about our competitive launch of Panopics Pro in Europe because I think we will do some positive momentum for Europe, which really has needed it. And I guess you're thinking probably about the U.S. launch of other products and same thing with Europe competitively. You know, my own point of view is we know both those products really well, and I think we've got them pretty much dialed into the forecast as we gave it. You know, my hope is that, you know, we see with TruPlus and with Penoptics Pro that we do a little better than expected, but we'll see. You know, these have been aggressive markets and aggressive competitors, and we wouldn't expect any less. So, you know, but we're doing well right now.

Thank you very much. The next question is from the line of Richard Felton with Goldman Sachs. Please receive your questions.

Thank you very much. Thanks for taking my questions. Two for me, please. The first one is on China IOLs. I know historically it was a relatively small part of your business, but I guess there's been a lot of growth for 80 IOLs and share gains for Alcom post-VBP. So any sense of how material that market is for you guys currently? And linked to that, any expectations for the upcoming round of China IOL VBP? And the next one, it would be great to get an update on Orion, please. What's the feedback been like on the commercial launch in Japan? Any incremental data or insights on efficacy versus transplants? And if possible, can you give us an update on the timeline for phase three trials in the U.S., please?

Yeah, just on China. Yeah, the IOLs are about the same as the full business, which is about 5%. So, you know, I would think about it as that. At one point, we really didn't have much of an IOL business there. We had a small bit, but I think we had a nice run with the VBP piece. It's picked up. Our share is pretty good. You know, we'll see what happens. That VBP rolls around again in the middle part of the year. So, you know, we'll certainly look forward to that. I think on the Arion piece, you know, what I would say is that we've started the phase three, the phase three already. We had our first dosings, I think, last, you know, earlier, last month, so middle of last month. So we're excited about that, that, you know, that's a product that I think if they finish the trial, you know, this year, you know, we have a potential to file it next year. That's a really exciting opportunity for us to help a lot of patients avoid a corneal transplant and do something really special for these patients.

Our next questions are from the line of Larry Beigleton with Wells Fargo. Please proceed with your questions.

Hi, it's Ray calling in for Larry. Thanks for taking the questions. I'll ask both up front, please. Just on the Unity, you sound very excited by the launch and seems to be doing well. Can you just talk about, you know, how you think about equipment growth for the remainder of the year with both of these products? and if you can give a timing update, whether it's US or US for some of the new Unity products that are coming to the market, like DS, et cetera. And my second question is around M&A. You know, Alcon has recently exited two deals, I mean, for different reasons, obviously. Do you think the space has become tougher in terms of M&A, maybe given Alcon's size or anything about the valuation environment, anything you're thinking differently in terms of how Alcon is approaching M-A going forward? Thank you.

Yeah, on Unity, you know, we expect Unity to continue to grow. I think, you know, we had talked a little bit last year about the number of placements. We're still kind of of that mind. You know, I don't know that we want to run through the whole thing, but remember, we've got 30,000-ish, you know, of a base that we will replace over 10 years. That's the normal cycle. you put a little more up front, you take a little away on the back end, and that's what we'll probably see in terms of placements. Now, you know, most of those are sold units. Some of them are rental units. Some of them are, you know, are leased. Those are all things that go on. But we feel really good about where we are relative to what we've said in the past on Unity and both its timing. And to be honest, the Unity CS piece is also exciting because, you know, we've kind of gotten through the heavy lifting on the retina side and, you know, we can do more of that, but there will be more of that. But I think we're now, you know, selling the cataract unit, which will be fun too. I think on the other pieces of that, Unity M is late this year. I would think about it as a first phase of a multi-phase launch. We are excited about it. This is going to be an exciting scope. We'll talk about it later in the year. And DX, I think, is slated for next year. You know, you'll start to see it later this year, but we're really doing a controlled launch on that one to make sure that that one's perfect. So I think, you know, we're going to be patient with DX and make sure that we get that one, you know, tied into our Audi planner and, you know, the microscope and a lot of the other stuff that it needs to integrate with. So we're being careful around that one. On M&A, I would just say that, you know, we haven't changed anything on M&A, really. Our own point of view is still that most of what we are interested in are kind of single product companies that are nice tuck-ins. They probably range, and we've often said this kind of 50 to 500 range, still pretty much the majority of what we do. We're very capable of doing something a bit larger than that, but, you know, we don't see any need to do that. And there, frankly, aren't that many targets that we pay attention to that are, you know, like that. So I would just say that, you know, STAR was one of the bigger ones that we talked about, you know, why that didn't happen. And, you know, Lenzar was just another one of these kind of smaller things that, you know, again, I will see what happens on that one. But I think that's a miss in terms of, you know, the opinion on where that sits in the market. I think, unfortunately, you know, there's a short life at this point for Femto relative to robotics, and we're really, you know, we're moving on to robotics at this point.

Thank you. Our last question comes from the line of Brett Fishbein with KeyBank Capital Markets. Please just hear your questions.

All right, great. Thanks for squeezing me in. I'll try and keep it fairly brief. So you took the tariff estimate down by $25 million within the guide and mentioned that the plan would be to reinvest within the business. So just curious where you saw incremental need for greater investment activity rather than, you know, potentially letting that drop down to earnings.

Yeah, I think a majority of that you're going to see in the R&D line. There's some innovation that we're very excited about. And, again, that drives the whole revenue thesis that we have. So we're going to continue to back that when we can.

All right, great. And then just follow up on margins, you know, you kept the 70 to 170 basis points core operating margin expansion guide. But I think since the last call, there have been, you know, noise around the macro, especially energy prices and concerns around inflation. So just curious how that's contemplated in the guide and any general thoughts on Alcon's exposure to those items.

Yeah, it's a great question. It's not really that material for us. It's primarily transportation and resins. So we will see, you know, we've assumed that oil is at a certain price and maintains that price through the course of the year. We've baked that into our guide. But it's not a material amount at this stage.

All right, great.

Thank you. At this time, I'll turn the floor to Dan Cravens for closing remarks.

Okay. Thanks, Rob, and thanks, everybody, for joining us. If you have any follow-up call or questions, please don't hesitate to call either Alan Tregg or myself. Thanks again for your time.

Appreciate the answer. Ladies and gentlemen, thank you for your participation. This does conclude today's teleconference. You may now disconnect your lines at this time and have a wonderful day.